Advertisement

Clinical Pharmacokinetics

, Volume 53, Issue 6, pp 553–563 | Cite as

Evidence-Based Morphine Dosing for Postoperative Neonates and Infants

  • Elke H. J. Krekels
  • Dick Tibboel
  • Saskia N. de Wildt
  • Ilse Ceelie
  • Albert Dahan
  • Monique van Dijk
  • Meindert Danhof
  • Catherijne A. J. Knibbe
Original Research Article

Abstract

Background and Objectives

From a previously validated paediatric population pharmacokinetic model, it was derived that non-linear morphine maintenance doses of 5 μg/kg1.5/h, with a 50 % dose reduction in neonates with a postnatal age (PNA) <10 days, yield similar morphine and metabolite concentrations across patients younger than 3 years. Compared with traditional dosing, this model-derived dosing regimen yields significantly reduced doses in neonates aged <10 days.

Methods

Concentration predictions of the population model were prospectively evaluated in postoperative term neonates and infants up to the age of 1 year who received morphine doses according to the model-derived algorithm. The efficacy of this dosing algorithm was evaluated using morphine rescue medication and actual average infusion rates.

Results

Morphine and metabolite concentrations were accurately predicted by the paediatric pharmacokinetic morphine model. With regard to efficacy, 5 out of 18 neonates (27.8 %) with a PNA of <10 days needed rescue medication versus 18 of the 20 older patients (90 %) (p = 0.06). The median (interquartile range [IQR]) total morphine rescue dose was 0 (0–20) μg/kg in younger patients versus 193 (19–362) μg/kg in older patients (p = 0.003). The median (IQR) actual average morphine infusion rate was 4.4 (4.0–4.8) μg/kg/h in younger patients versus 14.4 (11.3–23.4) μg/kg/h in older patients (p < 0.001).

Conclusion

Morphine paediatric dosing algorithms corrected for pharmacokinetic differences alone yield effective doses that prevent over-dosing for neonates with a PNA <10 days. The fact that many neonates and infants with a PNA ≥10 days still required rescue medication warrants pharmacodynamic studies to further optimize the dosing algorithm for these patients.

Keywords

Morphine Infusion Rate Rescue Medication Analgesic Efficacy Morphine Dose 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgments

We would like to thank René Mooren for analysing the plasma samples for morphine, M3G and M6G concentrations, and Ko Hagoort for critically reading the manuscript. This study was performed within the framework of the Dutch Top Institute Pharma project number D2-104. The work of C.A.J. Knibbe is supported by the Innovational Research Incentives Scheme (Veni grant, July 2006) of the Dutch Organisation for Scientific Research (NWO). None of the authors has any conflicts of interest that are directly relevant to the content of this article.

References

  1. 1.
    Ince I, De Wildt SN, Tibboel D, et al. Tailor-made drug treatment for children: creation of an infrastructure for data-sharing and population PK-PD modeling. Drug Discov Today. 2009;14:316–20.PubMedCrossRefGoogle Scholar
  2. 2.
    De Cock RF, Piana C, Krekels EH, et al. The role of population PK-PD modelling in paediatric clinical research. Eur J Clin Pharmacol. 2011;67:5–16.PubMedCentralPubMedCrossRefGoogle Scholar
  3. 3.
    Knibbe CA, Danhof M. Individualized dosing regimens in children based on population PKPD modelling: are we ready for it? Int J Pharm. 2011;415(1–2):9–14.PubMedCrossRefGoogle Scholar
  4. 4.
    Knibbe CA, Krekels EH, Danhof M. Advances in paediatric pharmacokinetics. Expert Opin Drug Metab Toxicol. 2011;7(1):1–8.PubMedCrossRefGoogle Scholar
  5. 5.
    Knibbe CA, Krekels EH, van den Anker JN, et al. Morphine glucuronidation in preterm neonates, infants and children younger than 3 years. Clin Pharmacokinet. 2009;48(6):371–85.PubMedCrossRefGoogle Scholar
  6. 6.
    Krekels EH, DeJongh J, van Lingen RA, et al. Predictive performance of a recently developed population pharmacokinetic model for morphine and its metabolites in new datasets of (preterm) neonates, infants and children. Clin Pharmacokinet. 2011;50(1):51–63.PubMedCrossRefGoogle Scholar
  7. 7.
    Ceelie I, de Wildt SN, van Dijk M, et al. Effect of intravenous paracetamol on postoperative morphine requirements in neonates and infants undergoing major noncardiac surgery: a randomized controlled trial. JAMA. 2013;309(2):149–54.PubMedCrossRefGoogle Scholar
  8. 8.
    Ceelie I, Van Dijk M, Bax NM, et al. Does minimal access major surgery in the newborn hurt less? An evaluation of cumulative opioid doses. Eur J Pain. 2011;15:615–20.PubMedCrossRefGoogle Scholar
  9. 9.
    Van Dijk M, De Boer JB, Koot HM, et al. The reliability and validity of the COMFORT scale as a postoperative pain instrument in 0 to 3-year-old infants. Pain. 2000;84:367–77.PubMedCrossRefGoogle Scholar
  10. 10.
    Lynn AM, Nespeca MK, Bratton SL, Shen DD. Intravenous morphine in postoperative infants: intermittent bolus dosing versus targeted continuous infusions. Pain. 2000;88:89–95.PubMedCrossRefGoogle Scholar
  11. 11.
    Olkkola KT, Maunuksela EL, Korpela R, Rosenberg PH. Kinetics and dynamics of postoperative intravenous morphine in children. Clin Pharmacol Ther. 1988;44:128–36.PubMedCrossRefGoogle Scholar
  12. 12.
    Kart T, Christrup LL, Rasmussen M. Recommended use of morphine in neonates, infants and children based on a literature review: part 2—clinical use. Paediatr Anaesth. 1997;7:93–101.PubMedCrossRefGoogle Scholar
  13. 13.
    Bouwmeester NJ, Van den Anker JN, Hop WC, et al. Age- and therapy-related effects on morphine requirements and plasma concentrations of morphine and its metabolites in postoperative infants. Br J Anaesth. 2003;90:642–52.PubMedCrossRefGoogle Scholar
  14. 14.
    Anand KJ. Pain panacea for opiophobia in infants? JAMA. 2013;309(2):183–4.PubMedCrossRefGoogle Scholar
  15. 15.
    Osborne R, Thompson P, Joel S, Trew D, Patel N, Slevin M. The analgesic activity of morphine-6-glucuronide. Br J Clin Pharmacol. 1992;34(2):130–8.PubMedCentralPubMedCrossRefGoogle Scholar
  16. 16.
    Murthy BR, Pollack GM, Brouwer KL. Contribution of morphine-6-glucuronide to antinociception following intravenous administration of morphine to healthy volunteers. J Clin Pharmacol. 2002;42(5):569–76.PubMedCrossRefGoogle Scholar
  17. 17.
    Smith MT, Watt JA, Cramond T. Morphine-3-glucuronide—a potent antagonist of morphine analgesia. Life Sci. 1990;47(6):579–85.PubMedCrossRefGoogle Scholar
  18. 18.
    Knibbe CA, Krekels EH, Danhof M. Advances in paediatric pharmacokinetics. Expert Opin Drug Metab Toxicol. 2011;7:1–8.PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2014

Authors and Affiliations

  • Elke H. J. Krekels
    • 1
    • 2
  • Dick Tibboel
    • 2
  • Saskia N. de Wildt
    • 2
  • Ilse Ceelie
    • 2
    • 3
  • Albert Dahan
    • 3
  • Monique van Dijk
    • 2
    • 4
  • Meindert Danhof
    • 1
  • Catherijne A. J. Knibbe
    • 1
    • 2
    • 5
  1. 1.Division of Pharmacology, Leiden Academic Center for Drug ResearchLeiden UniversityLeidenThe Netherlands
  2. 2.Intensive Care and Department of Pediatric SurgeryErasmus MC–Sophia Children’s HospitalRotterdamThe Netherlands
  3. 3.Department of AnesthesiologyLeiden University Medical CenterLeidenThe Netherlands
  4. 4.Department of Pediatrics, Division of NeonatologyErasmus MC–Sophia Children’s HospitalRotterdamThe Netherlands
  5. 5.Department of Clinical PharmacySt. Antonius HospitalNieuwegeinThe Netherlands

Personalised recommendations